Eli Lilly and Company $LLY Shares Purchased by OMERS ADMINISTRATION Corp

Key Points

• OMERS ADMINISTRATION Corp increased its stake in Eli Lilly and Company by 312.6% in Q1, acquiring 120,895 shares, bringing its total ownership to 159,567 shares valued at approximately $131.79 million.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Eli Lilly, with various ratings including one Strong Buy, fourteen Buy, and nine Hold, and a price target averaging $950.17.
• Eli Lilly announced a quarterly dividend of $1.50 per share, with the next payment scheduled for September 10th, resulting in an annualized yield of 0.8%.

OMERS ADMINISTRATION Corp grew its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 312.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 159,567 shares of the company's stock after buying an additional 120,895 shares during the period. Eli Lilly and Company accounts for approximately 1.2% of OMERS ADMINISTRATION Corp's holdings, making the stock its 29th biggest holding. OMERS ADMINISTRATION Corp's holdings in Eli Lilly and Company were worth $131,788,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. WestEnd Advisors LLC boosted its position in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company during the 1st quarter worth $27,000. Citizens National Bank Trust Department boosted its position in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company during the 1st quarter worth $40,000. Finally, Mascagni Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the 4th quarter worth $43,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. UBS Group decreased their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Finally, Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $950.17.

Insiders Place Their Bets

In related news, Director Jamere Jackson bought 200 shares of the business's stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Up 0.1%

Shares of Eli Lilly and Company stock traded up $0.45 during trading on Friday, reaching $732.41. The company had a trading volume of 2,548,350 shares, compared to its average volume of 6,895,566. The company has a market cap of $693.20 billion, a price-to-earnings ratio of 47.87, a price-to-earnings-growth ratio of 1.02 and a beta of 0.44. The firm's fifty day moving average is $748.68 and its 200-day moving average is $785.49. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $969.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.